Invesco Ltd. Has $81.11 Million Stake in BioLife Solutions, Inc. $BLFS

Key Points

• Invesco Ltd. has increased its stake in BioLife Solutions, Inc. by 9.6%, holding approximately $81.11 million worth of stock as of the most recent SEC filing.
• Despite a recent quarterly loss, BioLife Solutions reported revenue of $25.42 million, surpassing analysts' estimates of $23.71 million.
• Current analyst consensus rates BioLife Solutions as a "Moderate Buy" with a price target of approximately $31.29.

Invesco Ltd. raised its stake in BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report) by 9.6% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,551,054 shares of the medical equipment provider's stock after acquiring an additional 311,585 shares during the quarter. Invesco Ltd. owned approximately 7.48% of BioLife Solutions worth $81,106,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently made changes to their positions in BLFS. Rhumbline Advisers raised its holdings in BioLife Solutions by 0.7% in the 1st quarter. Rhumbline Advisers now owns 83,227 shares of the medical equipment provider's stock valued at $1,901,000 after buying an additional 566 shares during the last quarter. GAMMA Investing LLC raised its holdings in BioLife Solutions by 18.6% in the 1st quarter. GAMMA Investing LLC now owns 4,223 shares of the medical equipment provider's stock valued at $96,000 after buying an additional 663 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in BioLife Solutions by 5.4% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,508 shares of the medical equipment provider's stock valued at $532,000 after buying an additional 1,047 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in BioLife Solutions in the 4th quarter valued at approximately $31,000. Finally, Avantax Advisory Services Inc. raised its holdings in BioLife Solutions by 16.0% in the 1st quarter. Avantax Advisory Services Inc. now owns 9,077 shares of the medical equipment provider's stock valued at $207,000 after buying an additional 1,250 shares during the last quarter. Institutional investors own 93.24% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on BLFS. Zacks Research upgraded shares of BioLife Solutions to a "strong-buy" rating in a report on Monday, August 11th. HC Wainwright reiterated a "buy" rating and issued a $32.00 price objective (up previously from $30.00) on shares of BioLife Solutions in a report on Friday, August 8th. Wall Street Zen lowered shares of BioLife Solutions from a "hold" rating to a "sell" rating in a report on Wednesday, May 21st. Finally, Stephens assumed coverage on shares of BioLife Solutions in a report on Tuesday, July 22nd. They issued an "overweight" rating and a $30.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating and seven have assigned a Buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $31.29.

Insider Activity at BioLife Solutions

In other news, major shareholder Casdin Partners Master Fund, L sold 500,000 shares of the firm's stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $24.40, for a total transaction of $12,200,000.00. Following the completion of the sale, the insider owned 6,707,165 shares of the company's stock, valued at $163,654,826. This trade represents a 6.94% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Over the last three months, insiders have sold 2,008,831 shares of company stock worth $47,499,658. Company insiders own 2.20% of the company's stock.

BioLife Solutions Trading Up 0.5%

NASDAQ:BLFS traded up $0.12 on Thursday, reaching $25.08. 401,415 shares of the stock traded hands, compared to its average volume of 557,790. The firm has a market capitalization of $1.20 billion, a price-to-earnings ratio of -208.98 and a beta of 1.76. The company's 50 day moving average is $22.25 and its 200-day moving average is $23.42. BioLife Solutions, Inc. has a 1-year low of $19.10 and a 1-year high of $29.55.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last released its earnings results on Thursday, August 7th. The medical equipment provider reported ($0.33) earnings per share for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.31). The firm had revenue of $25.42 million for the quarter, compared to analyst estimates of $23.71 million. BioLife Solutions had a negative net margin of 5.39% and a positive return on equity of 0.16%. BioLife Solutions has set its FY 2025 guidance at EPS. On average, equities research analysts forecast that BioLife Solutions, Inc. will post -0.3 EPS for the current fiscal year.

BioLife Solutions Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.